Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Bayer AG | Silicon Valley Community Foundation | University of the Philippines
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Bayer AG | Silicon Valley Community Foundation | University of the Philippines
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Swiss TPH
Deal Size : Undisclosed
Deal Type : Partnership
Bayer and Swiss TPH to Develop Treatment Against Soil-Transmitted Helminths
Details : The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Swiss TPH
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Emodepside Phase II Trial for Treatment of Onchocerciasis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Bayer AG | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Bioavailability Study of Emodepside IR-tablets and Solution
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
December 26, 2017
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Bayer AG | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Bayer AG | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
December 26, 2017
Lead Product(s) : Emodepside
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Bayer AG | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emodepside
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Bayer AG | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Man Clinical Trial of Emodepside (BAY 44-4400)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 22, 2016
Lead Product(s) : Emodepside
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Bayer AG | Bill & Melinda Gates Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable